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709Everolimus-Eluting Stent Implantation for Unprotected
Left Main Coronary Artery Stenosis
The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery
Disease) Study
Objectives This study sought to evaluate the safety and efﬁcacy of second-generation drug-eluting
stents (DES) for patients with unprotected left main coronary artery (ULMCA) stenosis.
Background The clinical beneﬁt of second-generation DES for ULMCA stenosis has not been
determined.
Methods The authors assessed 334 consecutive patients who received everolimus-eluting stents
(EES) for ULMCA stenosis between 2009 and 2010. The 18-month incidence rates of major adverse
cardiac or cerebrovascular events (MACCE), including death, myocardial infarction (MI), stroke, or
ischemia-driven target vessel revascularization (TVR), were compared with those of a randomized
study comparing patients who received sirolimus-eluting stents (SES) (n  327) or coronary artery
ypass grafts (CABG) (n  272).
esults EES (8.9%) showed a comparable incidence of MACCE as SES (10.8%; adjusted hazard ratio
aHR] of EES: 0.84; 95% conﬁdence interval [CI]: 0.51 to 1.40; p  0.51) and CABG (6.7%, aHR of EES:
.40; 95% CI: 0.78 to 2.54; p  0.26). The composite incidence of death, MI, or stroke also did not
differ among patients receiving EES (3.3%), SES (3.7%; aHR of EES: 0.63; 95% CI: 0.27 to 1.47; p 
0.29), and CABG (4.8%; aHR of EES: 0.67; 95% CI: 0.29 to 1.54; p  0.34). However, the incidence of
ischemia-driven TVR in the EES group (6.5%) was higher than in the CABG group (2.6%, aHR of EES:
2.77; 95% CI: 1.17 to 6.58; p  0.02), but comparable to SES (8.2%, aHR of EES: 1.14; 95% CI: 0.64 to
2.06; p  0.65). Angiographic restenosis rates were similar in the SES and EES groups (13.8% vs.
9.2%, p  0.16).
Conclusions Second-generation EES had a similar 18-month risk of MACCE for ULMCA stenosis as
ﬁrst-generation SES or CABG. (Evaluation of Outcomes of EES Implantation for Unprotected Left
Main Coronary Artery Stenosis [PRECOMBAT-2]; NCT01348022) (J Am Coll Cardiol Intv 2012;5:
708–17) © 2012 by the American College of Cardiology FoundationV
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tive in patients with unprotected left main coronary artery
(ULMCA) stenosis (1–13). These trials have reported that
first-generation drug-eluting stents (DES) yielded favorable
mid- and long-term outcomes. For example, the left main
substudy of the SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery)
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710was noninferior to CABG in terms of 1-year incidence of
major adverse cardiac or cerebrovascular events (MACCE)
(12). These results have led to recently updated recommen-
dations that PCI may be considered an alternative to surgery
in patients who are not at high risk (14,15).
Despite these results, certain clinical issues regarding the
safety of first-generation DES for treatment of ULMCA
stenosis remain unresolved. Although stent thrombosis is
rare, its rate continues to increase and has been associated
with fatal consequences (16). Moreover, the need for repeat
revascularization remains higher after DES than after
CABG (6,12,13). Second-generation DES were therefore
designed to improve device perfor-
mance and clinical safety and effi-
cacy compared with first-generation
DES. Some studies have reported
that second-generation everolimus-
eluting stents (EES) are superior to
first-generation paclitaxel-eluting
stents in unselected patients (17,18).
EES is characterized by thinner
stent struts and a lower amount of
drug released through a less proin-
flammatory durable polymer com-
pared with first-generation DES.
However, because no data were
available on the use of second-
generation DES for patients
with ULMCA stenosis, the pro-
spective PRECOMBAT-2 (Pre-
mier of Randomized Comparison
of Bypass Surgery versus Angio-
plasty Using Everolimus-Eluting
Stent in Patients with Left Main
Coronary Artery Disease-2) trial
evaluated the safety and efficacy of
PCI using everolimus-eluting
Xience V stents (Abbott Vascular,
Santa Clara, California) for patients
with ULMCA stenosis. The results
were compared with those of his-
torical controls of patients receiving
PCI with SES or CABG in the PRECOMBAT randomized
study (12).
Methods
Study population. Between May 2009 and September 2010,
92 patients underwent ULMCA stenting with EES in 21
orean cardiac centers; of these patients, 334 who met the
nclusion and exclusion criteria of the PRECOMBAT ran-
omized trial (12) were entered into the prospective
RECOMBAT-2 registry study. The inclusion and exclusion
Abbreviations
and Acronyms
aHR  adjusted hazard ratio
CABG  coronary artery
bypass graft
CI  confidence interval
DES  drug-eluting stent(s)
DS  diameter stenosis
EES  everolimus-eluting
stent(s)
HR  hazard ratio
LAD  left anterior
descending coronary artery
MACCE  major adverse
cardiac or cerebrovascular
event(s)
MI  myocardial infarction
MLD  minimal lumen
diameter
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
TVR  target vessel
revascularization
ULMCA  unprotected left
main coronary arteryriteria of PRECOMBAT have been described (12). In arief, the trial included patients with angiographic UL-
CA stenosis (50% stenosis), who did not have ST-
egment elevation myocardial infarction (MI), cardiogenic
hock, another serious comorbidity, or contraindication to
ES. The institutional review board of each center ap-
roved the use of clinical data for this study, and all patients
rovided written informed consent.
Procedures. PCI procedures were performed in a standard-
zed manner (12). To decrease the influence of selection bias
etween EES patients and the historical controls of SES
nd CABG patients, EES were used as the default stent for
ll patients treated for ULMCA stenosis at the investigating
ites during the study period. We attempted to treat all
esions using SES in the PRECOMBAT study and EES in
he PRECOMBAT-2 study. The maximum length and
iameter of SES were 33 and 3.5 mm, respectively, and the
aximum length and diameter of EES were 28 and 4.0
m, respectively. Use of intravascular ultrasound, adjunc-
ive devices, or glycoprotein IIb/IIIa inhibitors was at the
perator’s discretion. All patients were prescribed aspirin
lus clopidogrel before or during the procedure. After PCI,
ll patients received 100 mg/day aspirin indefinitely and 75
g/day clopidogrel for at least 1 year.
Endpoints and deﬁnitions. The primary endpoint was
ACCE, including death from any cause, MI, stroke, or
schemia-driven target vessel revascularization (TVR) after
he procedure. The definitions of endpoints were identical
o those in the PRECOMBAT study (12). Deaths were
onsidered cardiac unless an unequivocal, noncardiac cause
as established. MI was defined as new Q waves and an
ncrease in creatine kinase-myocardial band concentration to
5 times the upper limit of the normal range, if occurring
ithin 48 h after the procedure, or as new Q waves or an
ncrease in creatine kinase MB concentration to greater than
he upper limit of the normal range, plus ischemic symp-
oms or signs, if occurring more than 48 h after the
rocedure. Stroke was defined as a neurological symptom
esulting from vascular lesions of the brain, persisting for
24 h. TVR, consisting of repeat revascularization of the
reated vessel with either PCI or CABG, was considered
schemia driven if the stenosis of any vessel was at least 50%
f the diameter of the vessel in the presence of ischemic
igns or symptoms or if the stenosis was at least 70% of the
iameter of the vessel in the absence of ischemic signs or
ymptoms. Clinically driven TVR was considered when the
reated vessels had stenosis of at least 50% in the presence of
schemic signs or symptoms. An independent clinical events
ommittee adjudicated all primary clinical endpoints. Adverse
vents were assessed in the hospital, at 30 days, and at 6, 9, and
2 months. Patients were asked to return for follow-up
ngiography 8 to 10 months after the PCI, or earlier if angina
ymptoms occurred. However, due to the tendency of in-stent
estenosis having a benign presentation in patients with ULMCA,
ngiographic surveillance was less strongly recommended in the
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711PRECOMBAT-2 than in the PRECOMBAT study (19). The
updated guideline does not recommend routine angiographic
follow-up because of its limited ability to predict stent throm-
bosis and good intermediate-term outcomes after ULMCA
stenting (15).
Angiographic analysis. Available angiograms were indepen-
dently analyzed at the angiographic core laboratory (Car-
dioVascular Research Foundation, Seoul, Korea). Quanti-
tative angiographic parameters, including minimal lumen
diameter (MLD), reference artery diameter, diameter ste-
nosis (DS), lesion length, and late luminal loss, were
measured at baseline, after the procedure, and during
Table 1. Baseline Clinical and Procedural Character
SES (n  327
Baseline characteristics
Age, yrs 62.0 10.0
Male 249 (76.1)
Diabetes mellitus 109 (33.3)
Hypertension 176 (53.8)
Hyperlipidemia 139 (42.5)
Current smoker 97 (29.7)
Previous PCI 42 (12.8)
Previous MI 16 (4.9)
Previous heart failure 0
Chronic renal failure 3 (0.9)
Peripheral vascular disease 15 (4.6)
Chronic lung disease 8 (2.4)
Acute coronary syndrome 155 (47.4)
Ejection fraction, % 61.5 8.4
EuroSCORE value 2.8 1.9
Chronic total occlusion 3 (0.9)
Multivessel disease* 231 (70.6)
Bifurcation left main stenosis* 219 (67.0)
SYNTAX score* 23.8 9.5
Stenting procedures
Total stent number in left main 1.6 0.8
Total stent number per patient 2.6 1.4
Intravascular ultrasound guidance 294 (89.9)
Two-stent technique for left main 112 (34.3)
Crush technique 37 (33.0)
Kissing stent 41 (36.6)
T stent 28 (25.0)
V stent 4 (3.6)
Culottes 1 (0.9)
Others 1 (0.9)
Angiographic follow-up 249 (76.1)
Values aremean SDor n (%). *p values for post-hoc comparisons: fo
CABG, and0.001 between EES versus CABG; for bifurcation left ma
0.008betweenEES versus CABG; and for SYNTAX score,0.001betwe
versus CABG. EES patients were enrolled in the PRECOMBAT-2 study
EES everolimus-eluting stent(s); CABG coronary artery bypass
PRECOMBAT Premier of Randomized Comparison of Bypass Surge
CoronaryArteryDisease; PRECOMBAT-2Premier of RandomizedCoin Patients with Left Main Coronary Artery Disease-2; SES sirolimus-elutingfollow-up in the main branch, including segments of the left
main and proximal left anterior descending artery (LAD)
and the side branch (usually the left circumflex artery) using
dedicated bifurcation angiographic software (CAAS version
5.4, Pie Medical, Maastricht, the Netherlands) (20). When
the left main lesion did not involve bifurcation stenosis,
analysis included the left main segment. Angiographic
restenosis was defined as 50% DS within the stented
segment, including the stent and the 5-mm proximal and
distal segments, on follow-up angiography. Patterns of
angiographic restenosis were quantitatively assessed using
the Mehran classification (21).
of the Patients
EES (n  334) CABG (n  272) p Value
62.9 10.4 62.5 9.4 0.49
236 (70.7) 209 (76.8) 0.15
116 (34.7) 82 (30.1) 0.48
189 (56.6) 140 (51.5) 0.45
149 (44.6) 107 (39.3) 0.43
75 (22.5) 74 (27.2) 0.10
27 (8.1) 34 (12.5) 0.098
13 (3.9) 17 (6.3) 0.41
4 (1.2) 2 (0.7) 0.15
4 (1.2) 2 (0.7) 0.84
6 (1.8) 7 (2.6) 0.097
4 (1.2) 7 (2.6) 0.40
151 (45.2) 147 (54.0) 0.084
61.1 8.2 60.8 8.4 0.67
2.9 2.0 2.9 2.0 0.71
1 (0.3) 1 (0.4) 0.50
191 (57.2) 205 (75.4) 0.001
240 (71.9) 163 (59.9) 0.008
21.1 8.8 26.8 10.4 0.001
1.8 0.9 — 0.003
2.3 1.3 — 0.006
302 (90.4) — 0.83
88 (26.3) — 0.027
53 (60.2)
18 (20.5)
7 (8.0)
2 (2.3)
1 (1.1)
7 (8.0)
203 (60.8) 51 (18.8) 0.001
essel disease,0.001 between SES versus EES, 0.20 between SES versus
sis, 0.17 between SES versus EES, 0.074 between SES versus CABG, and
versus EES,0.001betweenSES versus CABG, and0.001betweenEES
and CABG patients in the historical controls of PRECOMBAT study.
Imyocardial infarction; PCI percutaneous coronary intervention;
s Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main
nof Bypass Surgery versusAngioplastyUsing Everolimus-Eluting Stentistics
)
rmultiv
in steno
en SES
and SES
graft; M
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712Statistical analysis. As-treated groups were compared, re-
gardless of assigned randomization in the PRECOMBAT
study. We included patients comparable to the number of
patients in the PRECOMBAT study without sample size
justification. Clinical and angiographic characteristics are
presented as number and percentage or as mean  SD. For
continuous variables, differences among the 3 treatment
groups (EES, SES, and CABG) were evaluated by analysis
of variance, whereas differences between 2 groups (EES and
SES) were analyzed by Student t test. Differences in
categorical variables were analyzed using the chi-square test
or Fisher exact test, as appropriate. The clinical endpoints
Table 2. Quantitative Angiographic Analysis of the SES and EES Groups
SES EES p Value
Baseline n  286 n  311
Lesion length, mm
Main branch 28.5 15.7 23.5 15.9 0.001
Left circumﬂex 9.8 12.1 8.3 10.6 0.26
Reference, mm
Left main 3.64 0.49 3.71 0.46 0.12
LAD 3.16 0.49 3.18 0.51 0.55
Left circumﬂex 2.96 0.50 3.00 0.55 0.45
MLD, mm
Left main 1.68 0.63 1.72 0.55 0.46
LAD 1.66 0.78 1.77 0.77 0.087
Left circumﬂex 1.91 0.66 2.10 0.72 0.001
DS, %
Left main 53.8 16.3 53.5 14.0 0.83
LAD 47.2 23.4 44.6 22.0 0.17
Left circumﬂex 34.5 20.78 29.7 20.4 0.006
After procedure n  286 n  311
Stent length, mm
Left main 13.7 4.4 13.1 4.5 0.15
LAD 20.3 14.7 17.8 14.8 0.045
Left circumﬂex 10.5 11.6 6.8 8.4 0.001
MLD, in-stent, mm
Left main 3.24 0.45 3.32 0.48 0.036
LAD 2.76 0.49 2.81 0.56 0.25
Left circumﬂex 2.44 0.54 2.41 0.59 0.64
MLD, in-segment, mm
Left main 3.23 0.45 3.31 0.48 0.046
LAD 2.47 0.55 2.42 0.60 0.29
Left circumﬂex 2.24 0.55 2.23 0.57 0.86
DS, in-stent, %
Left main 9.4 9.4 6.1 9.8 0.001
LAD 10.1 9.4 5.9 9.8 0.001
Left circumﬂex 16.6 13.5 19.0 14.0 0.040
DS, in-segment, %
Left main 10.1 9.1 8.4 8.2 0.017
LAD 16.2 10.5 15.6 10.8 0.49
Left circumﬂex 21.0 12.9 23.4 13.0 0.028
Continued in the next columnwere compared using a log-rank test of time to first eventTable 2. Continued
SES EES p Value
At follow-up n  210 n  184
MLD, in-stent, mm
Left main 3.09 0.60 3.13 0.60 0.53
LAD 2.58 0.68 2.68 0.72 0.17
Left circumﬂex 2.16 0.66 2.20 0.63 0.54
MLD, in-segment, mm
Left main 3.08 0.60 3.13 0.60 0.48
LAD 2.35 0.65 2.32 0.60 0.63
Left circumﬂex 2.05 0.63 2.05 0.61 0.92
DS, in-stent, %
Left main 13.7 14.6 12.8 14.0 0.52
LAD 15.7 17.3 12.614.0 0.059
Left circumﬂex 25.7 20.8 26.6 17.7 0.67
DS, in-segment, %
Left main 14.5 14.4 14.2 12.8 0.83
LAD 20.2 16.7 20.1 13.7 0.99
Left circumﬂex 28.4 19.6 29.7 16.9 0.48
Late loss, in-stent, mm
Left main 0.19 0.55 0.19 0.43 0.89
LAD 0.21 0.59 0.12 0.57 0.16
Left circumﬂex 0.26 0.54 0.21 0.48 0.33
Late loss, in-segment, mm
Left main 0.19 0.56 0.18 0.43 0.83
LAD 0.13 0.57 0.06 0.42 0.23
Left circumﬂex 0.18 0.50 0.18 0.46 0.97
Restenosis n  210 n  184
Overall 29 (13.8) 17 (9.2) 0.16
Main branch 16 (7.6) 5 (2.7) 0.031
Left main 7 (3.3) 3 (1.6) 0.35
LAD 12 (5.7) 5 (2.7) 0.21
Location
Proximal edge 1 (0.5) 0 0.99
In-stent 15 (7.1) 4 (2.2) 0.022
Distal edge 0 1 (0.1) 0.47
Pattern
Focal 15 (7.1) 3 (1.6) 0.009
Diffuse 1 (0.5) 2 (1.1) 0.49
Proliferative 0 0
Total occlusion 0 0
Left circumﬂex 17 (8.1) 14 (7.6) 0.86
With stent (2-stent technique) 12/71 (16.9) 7/46 (15.2) 0.81
In-stent with ostial stenosis 11 (15.5) 4 (8.7) 0.28
In-stent without ostial stenosis 1 (1.4) 1 (2.2) 0.76
Distal edge 0 3 (6.5) 0.058
Without stent (single-stent technique) 5/139 (3.6) 7/138 (5.1) 0.55
Ostium 4 (2.9) 6 (4.3) 0.51
Non-ostium 1 (0.7) 1 (0.7) 0.99
Pattern
Focal 16 (7.6) 14 (7.6) 0.99
Diffuse 1 (0.5) 0 0.99
Proliferative 0 0
Total occlusion 0 0
Values are mean SD, n (%), or n/n (%). EES patients were enrolled in the PRECOMBAT-2 study
and SES patients in the historical control of PRECOMBAT study.
DSdiameter stenosis; LAD left anterior descending coronary artery;MLDminimal lumendiameter; other abbreviations as in Table 1.
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713from the time of the procedure. The Kaplan-Meier method
was used to estimate survival. Patients were censored at 18
months or at occurrence of an endpoint. Differences among
the groups in risk-adjusted, long-term rates of study out-
comes were assessed using multivariable Cox proportional
hazards regression with covariates that had a significant
effect (p  0.1) on clinical outcomes. Covariates considered
in the Cox models included patient age and sex; presence of
hypertension, smoking, hypercholesterolemia, and diabetes
mellitus; prior history of MI, stroke, peripheral vascular
disease, congestive heart failure, chronic renal failure,
chronic lung disease, bifurcation left main stenosis, multi-
vessel disease, and PCI; performance of angiographic sur-
veillance; and left ventricular ejection fraction. The multi-
variate models were confirmed by backward elimination.
The proportional hazards assumption was confirmed by
testing of partial (Schoenfeld) residuals, and no relevant
violations were found (22). No adjustments were made for
multiple comparisons in post hoc secondary analyses. SAS
software, version 9.1, was used for all statistical analyses
(SAS Institute Inc., Cary, North Carolina).
Results
Study patients. Baseline characteristics and procedural find-
ngs are shown in Table 1. The 3 groups were generally well
atched, except that EES patients were more likely to have
ifurcation left main stenosis, single-vessel involvement,
nd low SYNTAX scores than did SES or CABG patients.
ES patients received more stents per left main lesion, but
ewer stents per patient. Angiographic complete revascular-
zation was performed in 230 (70.3%) in SES, 240 (71.9%)
Table 3. Clinical Events Over 18 Months
Endpoints SES (n  327)
MACCE 35 (10.8)
Death, MI, or stroke 12 (3.7)
Death 7 (2.2)
Cardiac causes 4
Noncardiac causes 3
MI 4 (1.2)
Q-wave 2
Non–Q-wave 2
Stroke 1 (0.3)
Ischemia-driven TVR* 26 (8.2)
Left main 16
Non-left main 10
Clinically driven TVR 19 (6.0)
Deﬁnite stent thrombosis or
symptomatic graft occlusion
1 (0.3)
Values are n (%), as determined using the Kaplan-Meier method. p
comparisons were 0.41 between SES versus EES, 0.005 between SES v
PRECOMBAT-2 study, and SES and CABG patients in the historical conMACCEmajor adverse cardiac or cerebrovascular event(s); TVR targetn EES, and 185 (68.0%) in CABG patients (p  0.59).
Angiographic follow-up was less frequently performed in EES
patients than in SES patients at 9.4  2.1 months and 8.8 
2.8 months, respectively (p  0.014). Baseline angiographic
haracteristics of the main branch, including the left main and
AD, were well matched in SES and EES patients (Table 2).
owever, DS in the side branch and lesion length in the main
ranch were less severe in EES than SES patients.
Clinical outcomes. Table 3 and Figure 1 show clinical
utcomes over 18 months. Before adjustment, the 3 groups
ad comparable incidence rates of individual endpoints and the
omposite of death, MI, or stroke. However, the incidence of
schemia-driven TVR was lower in the CABG than in the
ES or EES group, but the clinically driven TVR rate did not
iffer significantly. The overall incidence of MACCE, the
rimary endpoint, did not differ among the 3 groups. There
ere no differences in clinical outcomes between the SES and
ES groups. When the risks of events were adjusted using the
ox proportional hazard model, the pattern of differences in
linical outcomes did not change (Fig. 2). In addition, com-
ared with CABG, PCI with EES was not associated with the
isk of death (hazard ratio [HR]: 0.59; 95% confidence interval
CI]: 0.21 to 1.63; p  0.31), composite of death, MI, or
troke (HR: 0.67, 95% CI: 0.29 to 1.54; p  0.34), and
ACCE (HR: 1.40; 95% CI: 0.78 to 2.54; p 0.27). But the
isk of ischemia-driven TVR was higher in the EES group
HR: 2.77; 95% CI: 1.17 to 6.58; p  0.021).
Angiographic outcomes after stenting. Table 2 shows the
quantitative angiographic outcomes in the SES and EES
groups. After the procedure, EES patients achieved lower
DS in the main branch, but higher DS in the side branch,
EES (n  334) CABG (n  272) p Value
29 (8.9) 18 (6.7) 0.23
11 (3.3) 13 (4.8) 0.63
7 (2.1) 9 (3.3) 0.57
5 7
2 2
4 (1.2) 4 (1.5) 0.95
2 4
2 0
2 (0.6) 1 (0.4) 0.84
21 (6.5) 7 (2.6) 0.019
21 3
0 4
11 (3.4) 7 (2.6) 0.101
0 3 (1.1) 0.105
were calculated using the log-rank test. *The p values for post hoc
BG, and 0.019 for EES versus CABG. EES patients were enrolled in the
RECOMBAT study.values
ersus CA
trols of Pvessel revascularization; other abbreviations as in Table 1.
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714than SES patients. Quantitative angiographic analyses at
follow-up were performed in 73% of SES and 59% of EES
patients, but there were no between-group differences in
angiographic parameters, including DS, MLD, and late loss
in any segment. Subsequently, the rate of overall restenosis
did not differ between the 2 groups. However, late loss and
restenosis rates in the main branch were slightly lower in
EES than in SES patients. In both groups, a focal pattern
was predominant in restenotic lesions.
Angiographic and clinical outcomes according to the stent
technique. When the stenting technique was separated into
the single- and 2-stent techniques, kissing stenting tech-
nique and crush technique were most popularly used in SES
and EES patients, respectively (Table 1). The restenosis
rates in the subgroups stratified by the stent technique are
illustrated in Figure 3. Ischemia-driven TVR occurred in 11
(5.3%) SES and 12 (5.1%) EES patients in the single-stent
15
10
5
0
15
10
5
0
0 180 360 540
At risk
SES 327 317 300
EES  334  316 191
CABG 272 261  249 
0 180 360 540
At risk
SES  327  296 276
EES  334  299 178
CABG 272 256  244 
A  
C     
SES Patients
EES Patients
CABG Patients
Figure 1. Event Rates Over 18 Months
(A) Death from any cause; (B) death, MI, or stroke; (C) ischemia-driven TVR; (D
p Values were calculated using the log-rank test for EES patients in the PRECO
ies. EES  everolimus-eluting stent(s); CABG  coronary artery bypass graft; M
Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients wi
Comparison of Bypass Surgery versus Angioplasty Using Everolimus-Eluting Ste
stent(s); TVR  target vessel revascularization.group (log-rank p  0.94) and 15 (13.6%) SES and 9(10.4%) EES patients in the 2-stent group (log-rank p 
0.51). Among them, TVR at left main was included in 5
SES and 12 EES patients in the single-stent group and in
11 SES and 9 EES patients in the 2-stent group.
Discussion
The major finding of this study is that using EES for
ULMCA stenosis is as safe and effective as employing SES
or CABG, as shown by the 18-month incidence of
MACCE. Although the need for repeat revascularization
was higher after EES than after CABG, second-generation
EES had risks of angiographic and clinical restenosis
comparable to those of first-generation SES.
Most studies evaluating the long-term outcomes of PCI
using DES for ULMCA stenosis have used first-generation
SES or paclitaxel-eluting stents (1–12). Previous random-
15
10
5
0
15
10
5
0
0 180 360 540
t risk
SES 327 312 293
EES  334  312 188
CABG 272 258  246 
0 180 360 540
t risk
SES  327  294 275
EES  334  297 176
CABG 272 253  241 
posite primary endpoint of major adverse cardiac or cerebrovascular events.
-2, and SES and CABG patients in the historical controls of PRECOMBAT stud-
yocardial infarction; PRECOMBAT  Premier of Randomized Comparison of
t Main Coronary Artery Disease; PRECOMBAT-2  Premier of Randomized
Patients with Left Main Coronary Artery Disease-2; SES  sirolimus-elutingA
A
   B
   D
) com
MBAT
I  m
th Lef
nt inized and registry studies found that these DES had similar
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715long-term safety and efficacy results (7,23). Despite the
trend toward higher late loss after paclitaxel-eluting stent
implantation, their clinical outcomes, including rates of
repeat revascularization, were similar. Nonetheless, PCI for
ULMCA stenosis, particularly with bifurcation involve-
ment, remains technically challenging and is related to
higher rates of stent thrombosis and repeat revasculariza-
Figure 2. Adjusted Hazard Ratios for Outcomes
Adjusted hazard ratios of EES in the PRECOMBAT-2 study compared with
SES in the historical control of PRECOMBAT study for the risk of events.
CI  conﬁdence interval; MACCE  major adverse cardiac or cerebrovascu-
lar event(s); other abbreviations as in Figure 1.
Left main 
(2.9% SES vs. 0.7% EES, p=0.18)
Left circumflex
(3.6% SES vs. 5.1% EES, p=0.55)
LAD
(5.0% SE
2.2% EES
Single-Stent Technique
(N=139 SES, 138 EES)
SES
Figure 3. Illustration of Angiographic Restenosis in the Subgroups Stratifie
Red and blue circles indicate the location of angiographic restenosis in patien
artery; other abbreviations as in Figure 1.tion. Therefore, studies assessing the safety and efficacy of
second-generation DES relative to first-generation DES for
ULMCA stenosis appear worthwhile. Compared with SES,
the reduced strut thickness (81 vs. 140 m) and thinner
polymer coating (7.6 vs. 12.6 m), in conjunction with
improved biocompatibility of the EES polymer, may favor-
ably affect neointimal hyperplasia. In addition, the availabil-
ity of a 4.0-mm EES stent might have achieved better stent
expansion and drug diffusion. In the PRECOMBAT study,
the maximal size of the SES used was 3.5 mm even in the
big left main lesions. Our study has the advantage of
comparing the outcomes of second-generation EES with
those of first-generation SES and CABG. Despite our
nonrandomized study design, the 3 patient groups—those
treated with EES in the PRECOMBAT-2 trial and those
treated with SES and CABG in the PRECOMBAT
study—were comparable, without a serious selection bias,
since both trials used the same inclusion and exclusion
criteria.
We found that the clinical and angiographic outcomes of
patients with ULMCA stenosis treated with second-
generation EES and first-generation SES were comparable
over 18 months. These 2 types of stents were recently
compared in patients with unselected lesions. For example,
the randomized ESSENCE-DIABETES (Everolimus-
Eluting Stent Versus Sirolimus-Eluting Stent Implantation
for De Novo Coronary Artery Disease in Patients With
Diabetes Mellitus) trial, involving 300 diabetic patients,
.34) 
Left main
(4.2% SES vs. 4.3% EES, p=1.0)
Left circumflex
(16.9% SES vs. 15.2% EES, p=0.81)
LAD
(7.0% SES vs. 
4.3% EES, p=0.55) 
Two-Stent Technique
(N=71 SES, 46EES)
EES
Stenting Technique
ated with SES and EES, respectively. LAD  left anterior descending coronaryS vs. 
, p=0
d By
ts tre
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716found a tendency toward lower restenosis rate, but similar
clinical outcomes, in the EES compared with the SES
group (24). Another large, as yet unpublished trial, SORT
OUT IV (the Scandinavian Organisation for Randomised
Trials with Clinical Outcome IV) study, involving 2,774
unselected patients, found that EES and SES yielded
similar 9-month incidence rates of death, MI, stent throm-
bosis, and TVR (25). The similar clinical outcomes of SES
and EES in these studies, as well as in ours, may be due
primarily to the comparable biological potency of everoli-
mus and sirolimus. Alternatively, as suggested in studies
comparing SES and paclitaxel-eluting stents for ULMCA
stenosis, large caliber in the left main coronary artery may
accommodate the impact of intimal tissue growth on net
clinical outcomes if similar stenting techniques are used
(7,19). Nonetheless, our finding of a slightly lower late loss
and restenosis rate in the main branch after EES implan-
tation suggests that different DES have different efficacies
for ULMCA stenosis. Further studies evaluating the angio-
graphic and clinical outcomes achieved using various DES
should clarify their differential efficacies.
PCI using EES had a similar incidence of death, MI, or
stroke, but a higher incidence of TVR, compared with
CABG. This pattern was in agreement with findings
comparing PCI using first-generation DES and CABG in
the PRECOMBAT and other trials (12,13). However, the
rate of clinically driven TVR, which excluded revasculariza-
tions for patients without objective recurrence of ischemic
symptom or sign, did not differ significantly between EES
and CABG patients. This indicates that the “oculostenotic
reflex” due to routine angiographic follow-up after stent
implantation might have exaggerated the difference of TVR
rates between CABG and EES patients. In fact, angio-
graphic follow-up was performed in 61% after EES and
19% after CABG procedures. The new practice guidelines
do not recommend routine angiographic surveillance even
after left main coronary stenting (14,26). Therefore, our
findings support the hypothesis of the ongoing randomized
Evaluation of XIENCE PRIME versus the EXCEL (Cor-
onary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization) trial, that PCI using EES is clinically
noninferior to CABG.
Study limitations. First, the nonrandomized study design
may have introduced biases into the results. Because we used
a historical control group of SES patients, the stent tech-
niques or medications in EES patients may have been
improved or modified. For example, due to the less rigorous
recommendation for routine angiographic follow-up, the
rate of TVR for restenosis in patients without inducible
ischemia may have been lower in EES than in SES patients.
In addition, due to a lack of power calculation, this study
may be underpowered in the comparison of clinical end-
points across the groups. Second, since we used the same
inclusion criteria as the previous randomized study, ourresults may have limited generalizability in real-world prac-
tice. Third, the shorter follow-up duration in EES patients
may have resulted in a lower incidence of adverse events
than observed in SES patients. Finally, the 18-month
follow-up period was not sufficient to assess the durable
safety and efficacy of DES. To compensate for these
limitations, a further randomized study with sufficient
sample size and follow-up period is warranted.
Conclusions
We found that second-generation EES for ULMCA ste-
nosis resulted in a similar risk of death, MI, stroke, or repeat
revascularization as first-generation SES or CABG. Further
randomized trials are needed to compare PCI using newer-
generation DES and CABG in patients with these complex
coronary lesions.
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